Weiss Ratings Reaffirms “Sell (E+)” Rating for 180 Life Sciences (NASDAQ:ATNF)

Weiss Ratings reissued their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNFFree Report) in a research note published on Wednesday morning,Weiss Ratings reports.

180 Life Sciences Price Performance

NASDAQ ATNF opened at $0.99 on Wednesday. The firm has a 50-day moving average price of $0.99 and a two-hundred day moving average price of $1.35. 180 Life Sciences has a 12-month low of $0.66 and a 12-month high of $17.75.

180 Life Sciences (NASDAQ:ATNFGet Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Anson Funds Management LP acquired a new stake in 180 Life Sciences Corp. (NASDAQ:ATNFFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned about 7.08% of 180 Life Sciences at the end of the most recent reporting period. Institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

(Get Free Report)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

Featured Stories

Receive News & Ratings for 180 Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 180 Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.